<DOC>
	<DOC>NCT00527605</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, six-month parallel-group study assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH) , followed by a 12-month open-label treatment phase</brief_summary>
	<brief_title>Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Inclusion: Clinical diagnosis of BPH AUASI &gt;=12 [American Urological Association Symptom Index] Qmax &gt; 5ml/sec and &lt;=15ml/sec and minimum voided volume of &gt;=125ml Prostate volume &gt;=30cm(3) Exclusion: Post void residual volume &gt;250ml History or evidence of prostate cancer Total serum PSA &lt;1.5ng/ml or &gt;10.0ng/ml (Prostate specific antigen) Previous prostatic surgery or other invasive procedures to treat BPH. History of AUR (Acute Urinary Retention) within 3 months History of flexible/rigid cystoscopy or other instrumentation of the urethra within 7 days Any causes other than BPH, which may in the judgement of the investigator, result in urinary symptoms or changes in flow rate History of hepatic impairment or abnormal liver function tests Use of any 5areductase inhibitors ,any drugs with antiandrogenic properties or other drugs noted for gynaecomastia effects, or could affect prostate volume, within past 6 months and throughout the study Use of alphareceptor blockers within 2 weeks and throughout the study. Use of phytotherapy for BPH within 2 weeks and/or predicted to need phytotherapy during the study. Concurrent use of anabolic steroids Use of any alphaadrenergic agonists or cholinergics within 48 hours prior to uroflowmetry assessment. Hypersensitivity to any 5areductase inhibitor or other chemicallyrelated drugs. Actively trying to procreate or unwilling to wear a condom during intercourse with a woman of childbearing potential for duration of participation in this study and 16 weeks following treatment. History or current evidence of drug or alcohol abuse within the previous 12 months. History of any illness that in the opinion of the investigator might confound the results of the study or poses additional risk to the patient. Any unstable, serious coexisting medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, of cerebrovascular accident within 6 months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management. History of renal insufficiency, or serum creatinine &gt;1.5xULN (Upper Limit of Normal ) Participation in any investigational or marketed drug trial within 30 days and during the course of the study.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>placebo control</keyword>
	<keyword>Chinese</keyword>
	<keyword>Dutasteride</keyword>
	<keyword>Randomized</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Double blind</keyword>
</DOC>